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We have developed a system in which the fusion of pancreatic zymogen granules with plasma membranes can be studied in vitro. Here we show 
that this membrane fusion event is stimulated specifically by peptides of the effector domain of rab3, a small, monomeric GTP-binding protein. 
In addition, we demonstrate that the stimulatory effect of the peptides involves their binding to a target on the plasma membrane, and is both 
qualitatively and quantitatively different from the effect of GTPyS, which also enhances membrane fusion. We suggest that regulated exocytosis 
in the pancreatic acinar cell may be under the control of more than one type of GTP-binding protein. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Members of the super-family of small (20-30 kDa), 
monomeric GTP-binding proteins are known to be in- 
volved in the control of intracellular membrane traffic 
[1,2]. These proteins include the products of the yeast 
Sec4 [3] and YPTl [4] and the various rab proteins, each 
of which is localized to a specific membrane compart- 
ment [5]. The control of membrane fusion during regu- 
lated exocytosis appears to involve rab3. This protein 
is found, for example, on the membranes of synaptic 
vesicles [6], and has been shown to dissociate from these 
vesicles during exocytosis [7]. In addition, several mon- 
omeric GTP-binding proteins have been found on the 
membrane of the pancreatic zymogen granule [S], one 
of which appears to be rab3-like [9,10]. Finally, it has 
recently been reported that peptides of the rab3 effector 
domain stimulate exocytosis in pancreatic acini [9], in 
chromaffin cells [l l] and in mast cells [12]. These find- 
ings have been taken to indicate that G,, the elusive 
GTP-binding protein believed to be involved in the con- 
trol of exocytosis [13], might be a rab-like protein. We 
have developed a system in which the fusion of zymogen 
granules with plasma membranes can be studied in vitro 
[14,15]. Here we show that this membrane fusion event 
is stimulated specifically by peptides of the rab3 effector 
domain, but that their effects are both qualitatively and 
quantitatively different from that of GTP@. 
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Peptide synthesis was performed on an SMPS Multiple Peptide 
Synthesis machine (Zinsser Analytic, Maidenhead, UK) using Fmoc 
chemistry. Purity was demonstrated by analytical HPLC (Waters. 
Milford, MA, USA). Sequence identity was verified by Edman degra- 
dation on an automated gas-phase protein sequencer (Applied Biosys- 
terns, Warrington, UK). 
Zymogen granules, plasma membranes and zymogen granule mem- 
branes were prepared from rat pancreas as described previously [14]. 
Granules prepared from a single rat (300 ~1 suspension in 280 mM 
sucrose, 5 mM MES buffer, pH 6.0; total protein concentration ap- 
prox 5 mg/ml) were loaded with octadecylrhodamine B-chloride (100 
PM) by incubation at 37°C for 5 min. Labelled granules were recov- 
ered by centrifugation at 900 x g for IO min and resuspended in the 
original volume of buffer. Plasma membranes and granule membranes 
were stored in aliquots at -20°C and thawed immediately before use. 
De-quenching assays were carried out using a Perkin-Elmer (Beacons- 
field, UK) LS-3 luminescence spectrometer connected to a pen re- 
corder. Wavelengths used were 560 nm (excitation) and 590 nm (emis- 
sion). Samples of labelled granules (10 ~1) were added to 700 ~1 su- 
crose/MES buffer, pH 6.5, at 37°C and a steady baseline was obtained. 
Peptides were then added, followed approximately 30 s later by a 
sample of target membranes. The fluorescence signal was usually 
followed for 5 min. De-quenching was expressed as a percentage of 
that achieved after solubilization of membranes by addition of 0.2% 
Triton X-100. All errors given are standard errors of the mean. Initial 
quenching was typically 95%. As explained previously [15], de-quench- 
ing values underestimate the extent of membrane fusion, and can be 
regarded essentially as arbitrary units. 
3. RESULTS 
In this study, membrane fusion was measured directly 
using a fluorescence dequenching technique [16]. The 
membranes of isolated pancreatic zymogen granules 
were loaded with the lipid-soluble fluorescent probe oc- 
tadecylrhodamine B-chloride, at a concentration that 
resulted in the self-quenching of its fluorescence. The 
Published bl: Eisevier Science Publishers B. V. 
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Fig. 1. Effects of peptides derived from small GTP-binding proteins 
on fusion between pancreatic zymogen granules and plasma mem- 
branes. Membrane fusion was measured through the de-quenching of 
the lipid-soluble probe octadecylrhodamine B-chloride, loaded into 
the membranes of the zymogen granules. Peptides are: ARF, effector 
domain of ADP-ribosylation factor (IPTIGFNVETVQYKNI, single 
letter amino acid code); rabZAL, effector domain of rab2 with AL 
substituted for TI at positions 3 and 4 (DLALGVEFGARMITID); 
rab3a(C), C-terminal domain of rab3a (TDQQAPPHGDCAC); 
rab3b(C), C-terminal domain of rab3b (SDTPPLLQQNCSC); 
rab3AL, effector domain of rab3 with AL substituted for TV at posi- 
tions 3 and 4 (VSALGIDFKVKTIYRN); rab3, authentic effector 
domain of rab3 (VSTVGIDFKVKTIYRN). All peptide concentra- 
tions were 100 PM. Pancreatic plasma membranes (10 &ml protein) 
were added at the time indicated by the arrow. The basal fluorescence 
at the time of addition of membranes is indicated for each trace by the 
bar. 
granules were then incubated at 37°C with unlabelled 
target membranes and fusion was measured through the 
dilution-dependent de-quenching of the fluorescence of 
the probe. We have shown previously [ 151 that granules 
fuse with pancreatic plasma membranes, but not with 
plasma membranes from liver or chromaffin cells. 
Granules will, however, also fuse with unlabelled gran- 
ule membranes. Membrane fusion is unaffected by var- 
iations in Ca2+ concentration, but is stimulated by 
GTPyS over the same concentration range as that 
which stimulates exocytosis from permeabilized acini 
P71. 
Fig. 1 illustrates the effects of several peptides, all at 
a concentration of 100 PM, on the fluorescence de- 
quenching signal given by plasma membranes. In this 
typical experiment, four of the six peptides tested - the 
effector domain of the small GTP-binding protein 
ADP-ribosylation factor (ARF), rab2AL (a modified 
effector domain of the protein rab2) and the C-terminal 
domains of rab3a and rab3b - had no detectable effect 
on the de-quenching caused by the membranes. In con- 
trast, the effector domain of rab3 and the closely related 
peptide rab3AL both enhanced dequenching, with rab3 
giving the bigger enhancement. Mean values for the 
effects of the peptides on de-quenching, as a percentage 
of the total fluorescence, are: rab3, 1.1 k 0.3% (n = 4); 
rab3AL, 0.5 k 0.1% (n = 4); ARF 0.1 k 0.1% (n = 4); 
rab2AL, 0.1 k 0.1% (n = 4); rab3a (C), 0.0% (n = 2) and 
rab3b(C) 0.2% (n = 2). None of the peptides had any 
significant effect on the basal fluorescence given by la- 
belled granules alone. 
The dependence of the stimulation of de-quenching 
by rab3 and rab3AL on peptide concentration, at a 
single plasma membrane concentration, is shown in Fig. 
2. The effects of both peptides were maximal at about 
50 ,uM, with rab3 causing a larger maximal stimulation. 
Peptide concentrations giving half-maximal stimulation 
(EC,,+) were 20 PM for rab3 and 15 PM for rab3AL. 
Fig. 3 shows the effects of the two peptides, at 50 PM, 
on the relationship between de-quenching and plasma 
membrane concentration. Both peptides increased the 
maximal de-quenching caused by the membranes, with- 
out significantly affecting the EC,, for membranes (4 
pug/ml, as found previously [15]); once again, rab3 
caused a larger stimulation than rab3AL. This effect of 
the peptides on the concentration-response relationship 
for membranes contrasts with that of GTPyS, which 
does not affect the maximal signal, but reduces the EC,, 
u51. 
The concentration range over which the rab3 effector 
peptides stimulate membrane fusion (lo-100 ,uM) is 
identical to the range that has been reported to stimu- 
late amylase secretion in permeabilized acini [9]. This 
result indicates that the same process is being studied in 
the two systems, and that the effect of the peptides on 
secretion is through a direct effect on granule-plasma 
membrane fusion. In contrast to the results obtained 
with the permeabilized cell system, however, the authen- 
tic effector domain, and not the peptide with the AL 
modification, consistently produces the larger effect on 
membrane fusion. In order to obtain further informa- 
tion about how both the rab3 peptide and GTPyS act 
on the membranes, their effects on granule-plasma 
membrane fusion were compared with their effects on 
granule-granule membrane fusion. Optimal concentra- 
tions of both agents were used. In the experiment shown 
in Fig. 4a, GTPyS (100 ,uM) caused a small stimulation 
of the de-quenching produced by plasma membranes, 
whereas rab3 (50 ,uM) caused a larger stimulation. 
Mean effects on de-quenching, as a percentage of total 
fluorescence, were 0.2 k 0.0% (n = 6) for GTPyS and 
1.0 k 0.2% (n = 6) for rab3. The stimulation produced 
by GTPyS is in good agreement with that reported 
previously for the concentration of plasma membranes 
used [ 151, and the enhancement of de-quenching by rab3 
is similar to that reported above (see Fig. 1). A different 
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Fig. 2. Concentration-effect relationships for rab3 and rab3AL effec- 
tor peptides. (a). Typical traces for rab3. (b) Typical traces for 
rab3AL. (c) Combined data for rab3 (m, n = 5) and rab3AL (A, n = 4). 
Plasma membrane protein concentration was constant at 5 &ml. 
picture emerged when granule membranes were used as 
the unlabelled target (Fig. 4b). Now GTPyS caused a 
clear stimulation, whereas rab3 did not (in fact, in the 
experiment shown, de-quenching was reduced). Mean 
effects on de-quenching were 0.3 ? 0.2% (n = 5) for 
GTPyS and 0.0 f 0.2% (n = 5) for rab3. 
Evidence has been presented previously [ 14,151 that 
GTPyS has its effect through GTP-binding proteins lo- 
cated both on the granule membrane and the plasma 
membrane, and the data shown here are consistent with 
this idea. The fact that the rab3 peptide stimulates only 
fusion between granules and plasma membranes sug- 
gests that its target is found only on the plasma mem- 
branes. A clear prediction of this hypothesis is that 
pre-incubation of plasma membranes with the peptide 
should enhance the de-quenching signal produced, but 
that pre-incubation of granule membranes with the pep- 
tide should be ineffective. This prediction was tested in 
the experiment shown in Fig. 4c and d and found to be 
upheld. Mean values for the effects of pre-incubation of 
the membranes with rab3 on the size of the de-quench- 
ing signal were a 0.3 + 0.1% (n = 5) increase for plasma 
membranes and a 0.1 + 0.1% (n = 5) decrease for gran- 
ule membranes. The fact that pre-incubation of the 
plasma membranes with the rab3 peptide was less effec- 
tive than adding the peptide to the fusion assay mix 
(compare Fig. 4c with Fig. 1) can be accounted for 
either by a rapid dissociation of the peptide from its 
binding site following the dilution of the membranes or 
by a deterioration in the state of the membrane during 
the pre-incubation period. Since pre-incubation caused 
no significant reduction in the size of the de-quenching 
signal given by membranes alone, however, the former 
explanation seems more likely. 
4. DISCUSSION 
According to the model for vesicular transport origi- 
nally proposed by Bourne [l], vesicles bearing a mon- 
omeric GTP-binding protein in its GTP-bound form 
dock with the target membrane; GTP hydrolysis then 
occurs, allowing membrane fusion; finally, the GDP- 
bound form of the protein dissociates from the mem- 
brane and recycles to initiate another round of trans- 
port. The GTPase activity of the GTP-binding protein 
is believed to be stimulated by a protein present on the 
target membrane, known as a GTPase activating pro- 
tein, or GAP [18,19]. In support of this model, it has 
been shown, for example, that both ER-Golgi [20] and 
intra-Golgi [21] membrane transport steps on the con- 
stitutive pathway are blocked by GTPyS, presumably 
because the bound GTPyS cannot be hydrolysed. The 
rab3AL effector peptide also blocks ER-Golgi trans- 
port [22], perhaps by binding to a GAP and inhibiting 
its action on the GTP-bound rab protein. In order to 
extend this model to the membrane fusion event in- 
volved in regulated exocytosis, which in the exocrine 
pancreas is stimulated by both GTPyS and rab effector 
peptides, one would have to propose that the GTP- 
bound form of rab promotes fusion and that GTP hy- 
drolysis terminates its action. Such a proposal has al- 
ready been outlined in an attempt to explain the effects 
of these peptides on exocytosis [9,11,12]. 
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Fig. 3. Concentrationeffect relationships for plasma membranes in 
the absence and presence of the rab3 and rab3AL effector peptides. 
(e) control (n = 6) (m) rab3 (n = 3) and (A) rab3AL (n = 4). Peptide 
concentrations were constant at 50 flM. 
An important advantage of the in vitro fusion assay 
used here is that it permits a study of the effects of these 
agents on each of the two interacting membranes. From 
this study it is apparent that GTPyS and the rab effector 
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peptides do not have the same effect, which indicates 
that membrane fusion may be under the control of more 
than one GTP-binding protein. We have reported previ- 
ously [14] that the effect of GTPyS on zymogen gran- 
ule-plasma membrane fusion is mimicked by the 
[AIF,]- ion. This is now known to be a characteristic of 
the involvement of heterotrimeric GTP-binding pro- 
teins, that are active in the GTP-bound state [23]. We 
propose, therefore, that at least a major part of the 
effect of GTPyS on membrane fusion is mediated 
through an effect on a heterotrimeric GTP-binding pro- 
tein. The evidence available further indicates that the 
effect of GTPyS involves its binding to both the granule 
membrane and the plasma membrane. The effect of the 
rab peptides, on the other hand, is apparently restricted 
to the plasma membrane. This would of course be ex- 
pected if its target were a GAP-like protein, although 
this has not yet been demonstrated. Further work will 
be necessary both to identify this target and to under- 
stand fully how these peptides are producing their ef- 
fects. 
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Fig. 4. Effects of rab3 effector peptide and GTPyS on membrane fusion. (a) Granule&plasma membrane fusion. Peptide (50pM) and GTPyS (100 
PM) were added 30 s before target membranes. (b) Granule-granule membrane fusion. (c) Fusion of granules with plasma membranes that had 
been pre-incubated with rab3 effector peptide (50 PM) for 15 min at 37°C. The final concentration of peptide in the incubation mix was 0.5 PM, 
which, without pre-incubation, will not enhance fusion (see Fig. 2). (d) Fusion of granules with granule membranes that had been pre-incubated 
with rab3 effector peptide as described above. Plasma membrane protein concentration was 10 ,&ml; granule membrane protein concentration 
was 5 ,@ml. 
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